Systematic review of palm oil consumption and the risk of cardiovascular disease

Sophia Rasheeqa Ismail¹*, Siti Khuzaimah Maarof²*, Syazwani Siedar Ali²*, Azizan Ali¹

¹ Cardiovascular, Diabetes & Nutrition Research Centre, Institute for Medical Research, Kuala Lumpur, Malaysia, ² Herbal Medicine Research Centre, Institute for Medical Research, Kuala Lumpur, Malaysia

* These authors contributed equally to this work.
* Sophia.rasheeqa@imr.gov.my

Abstract

Background

The high amount of saturated fatty acids (SFA) coupled with the rising availability and consumption of palm oil have lead to the assumption that palm oil contributes to the increased prevalence of cardiovascular diseases worldwide. We aimed at systematically synthesising the association of palm oil consumption with cardiovascular disease risk and cardiovascular disease-specific mortality.

Methods

We systematically searched Central, Medline and Embase databases up to June 2017 without restriction on setting or language. We performed separate searches based on the outcomes: coronary heart disease and stroke, using keywords related to these outcomes and palm oil. We searched for published interventional and observational studies in adults (Age: >18 years old). Two investigators extracted data and a consensus was reached with involvement of a third. Only narrative synthesis was performed for all of the studies, as the data could not be pooled.

Results

Our search retrieved 2,738 citations for stroke with one included study and 1,777 citations for coronary heart disease (CHD) with four included studies. Palmitic acid was reported to be associated with risk of myocardial infarction (MI) (OR 2.76; 95%CI = 1.39–5.47). Total SFA intake was reported to be not significant for risk of MI. Varying intake of fried foods, highest contributor to total SFA with 36% of households using palm oil for frying, showed no significant associations to risk of MI. Odds of developing first non-fatal acute MI was higher in palm oil compared to soybean oil with 5% trans-fat (OR = 1.33; 95%CI = 1.09–1.62) than palm oil compared to soybean oil with 22% trans-fat (OR = 1.16; 95%CI = 0.86–1.56). Nevertheless, these risk estimates were non-significant and imprecise. The trend amongst those taking staple pattern diet (characterised by higher palm oil, red meat and added sugar consumption) was inconsistent across the factor score quintiles. During the years of 1980 and 1997, for every additional kilogram of palm oil consumed per-capita annually, CHD
mortality risk was 68 deaths per 100,000 (95% CI = 21–115) in developing countries and 17 deaths per 100,000 (95%CI = 5.3–29) in high-income countries, whereas stroke was associated with 19 deaths per 100,000 (95%CI = -12–49) and 5.1 deaths per 100,000 (95% CI: -1.2–11) respectively.

The evidence for the outcomes of this review were all graded as very low. The findings of this review should be interpreted with some caution, owing to the lack of a pooled effect estimate of the association, significant bias in selection criteria and confounding factors, inclusion of other food items together with palm oil, and the possible out-dated trend in the ecological study.

**Conclusion**

In view of the abundance of palm oil in the market, quantifying its true association with CVD outcomes is challenging. The present review could not establish strong evidence for or against palm oil consumption relating to cardiovascular disease risk and cardiovascular disease-specific mortality. Further studies are needed to establish the association of palm oil with CVD. A healthy overall diet should still be prioritised for good cardiometabolic health.

**Introduction**

Palm oil derives from the palm tree fruit (Elaeis guineensis) with a balanced ratio of unsaturated and saturated fatty acids: 40% oleic acid (monounsaturated fatty acid), 10% linoleic acid (polyunsaturated fatty acid), 45% palmitic acid and 5% stearic acid (saturated fatty acid) [1]. Palm oil is commonly used in margarines, shortening, vanaspati, frying fats, and confectionary fats [2]. Among the major oilseed crops, the palm tree fruit accounts for the smallest percentage (5.5%) of all the cultivated land for oils and fats globally, but produces the largest percentage (32%) of total output [3]. These advantages have lead palm oil to be the most widely consumed vegetable oil in the world [4].

Cardiovascular diseases (CVD), responsible of 31% of global deaths [5], are a group of diseases of the heart and blood vessels that include coronary heart disease (CHD), cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, congenital heart disease, deep vein thrombosis and also pulmonary embolism. CHD develops from the occlusion of coronary vessels by atherosclerotic plaques [6]. Whereas aetiology of stroke is dependent on the type of stroke: occlusion of vascular supply by atherosclerotic plaques for ischaemic strokes, and rupture of a blood vessel for haemorrhagic strokes [7].

High intake of saturated fatty acid has been linked to increased cholesterol levels, an important precursor of CVD [8, 9]. As a result, dietary recommendations have limited the intake of saturated fatty acids for the prevention of CVD. The World Health Organisation 2003 report stated that there is convincing evidence that palm oil consumption contributes to an increased risk of developing CVD [10]. Following suit, a number of studies suggested the association of high contents of saturated fats in palm oil with the detrimental atherogenic profile [11, 12].

A number of reviews have looked into the relationship between palm oil consumption and indirect cardiovascular outcomes such as changes in cholesterol levels [13–15]. However, to this date, the evidence associating palm oil consumption with CVD risk and CVD-specific mortality has not been systematically reviewed. This review aims at synthesising the available
evidence reporting the association of palm oil consumption with CVD risk and CVD-specific mortality, including specifically CHD and stroke.

**Methodology**

We conducted and reported this review in accordance to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [16]. The protocol of this review was prospectively registered at PROSPERO with registration number CRD42017058099. PRISMA Checklist is found in S1 Table.

**Eligibility criteria**

We included published interventional and observational studies that evaluated palm oil consumption with coronary heart disease or stroke. Interventional studies (defined as randomised-controlled trials, cluster-randomised trials, crossover studies, and quasi-experiments) that compared palm oil consumption to other vegetable oils such as canola, olive, sunflower and soybean oil were included. Observational studies included cohort studies, cross-sectional studies, case control and case series. We excluded conference abstracts, reviews, animal studies, in vivo/ in vitro studies, and qualitative studies (i.e. interviews, surveys). We included adult participants (age: >18 years old) with or without existing cardiovascular disease and all studies that had a clear consumption of palm oil for cooking or eating. We included all studies comparing palm oil with other types of vegetable oils, such as sunflower oil, canola oil, soybean oil, olive oil. Primary endpoints were risk of CHD or stroke (expressed as risk ratio, prevalence rate, incidence rate or hazard ratio) and cause specific death rates (defined as number of CHD or stroke deaths attributable to palm oil consumption within the population at risk).

**Data sources and search strategy**

We identified relevant articles relating to coronary heart disease and published in PubMed/MEDLINE, Embase and Central Cochrane databases. The search stopped on 9th June 2017, 8th June 2017 and 9th June 2017 respectively. We used the following combinations of keywords: {[Palm AND (oil OR olein OR stearin OR kernel)] OR tocotrienol OR Elaeis guineensis OR [(palmitic OR lauric OR myristic OR linoleic OR palmitoleic OR oleic) AND acid]} AND {[Myocardial infarction (MeSH) OR myocardial infarct* OR [coronary infarct*] OR [heart infarct*] OR [coronary syndrome] OR [heart attack] OR [STEMI] OR [NSTEMI]] in PubMed MEDLINE, and {[palm AND (olein OR stearin OR kernel)] OR [exp palm oil] OR [exp alpha tocotrienol] OR [exp Elaeis guineensis] OR [exp palmitic acid] OR [exp lauric acid] OR [exp myristic acid] OR [exp linoleic acid] OR [exp palmitoleic acid] OR [exp oleic acid]} AND {[exp heart infarction] OR [exp ischemic heart disease] OR [exp heart muscle ischemia] OR [exp ST segment elevation myocardial infarction] OR [exp coronary artery disease] OR [coronary adj3 syndrome] OR [heart attack] OR [exp non ST segment elevation] OR [myocardial infarction] in Embase. We further identified relevant articles relating to stroke and published in PubMed/MEDLINE, Embase and Central Cochrane databases. The search stopped on 3rd March 2017, 3th March 2017 and 14th March 2017 respectively. We used the following combinations of keywords: {[Stroke(MeSH Terms)] OR [mini-stroke] OR [minor-stroke] OR [ministroke] OR CVA OR TIA OR [attack, transient ischemic (MeSH Terms)] OR [transient ischaemic attack] OR [intracranial thrombus] OR [intracranial embolus] OR [(brain OR cerebral OR vascular OR cerebrovascular) AND (accident OR disease OR disorder)] OR [(brain OR cerebellar OR intracerebellar OR intracranial OR subarachnoid) AND (hematoma OR bleed* OR
We systematically searched for articles without any restriction to the year of publication or language, and supplemented by searching of reference lists of relevant studies. We searched using a strategy combining the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximising version [17] with selected MeSH terms and free text terms relating to palm oil, CHD and stroke.

Study selection
A pair of authors independently assessed the titles and abstracts of a defined set of articles using a planned search strategy. Each study was recorded as include, exclude or unclear. Any disagreement in the assessment was resolved by discussion leading to a consensus, with a third party serving as arbitrator if necessary. After the initial screening process, full articles of the included and unsure articles were retrieved for further assessment. Eligible studies were identified based on the inclusion criteria. Any disagreement in the assessment was resolved by discussion leading to a consensus.

Data extraction and risk of bias assessment
We performed narrative analysis and critical appraisal of the included articles by extracting all relevant information using a predesigned data extraction form and assessing risk of bias using standardised forms (Available from: http://www.casp-uk.net/casp-tools-checklists). Each article was assessed according specified form and its instructions. The details of this assessment are reported in S2 Table.

We independently extracted the data using a pre-designed Data Extraction Form which included study characteristics (type of study, method of participant selection, study duration, sample size, control group selection, objectives, outcomes measured and sources of funding), participant characteristics (country, study setting, inclusion criteria, and exclusion criteria), and analysis and results (method of analysis, endpoints of study, baseline characteristics of population studied, and confounding factors).

We independently assessed risk of bias for the included articles. One author in the team crosschecked the results of the assessment with disagreement resolved via discussion leading to a consensus. We performed risk of bias assessments using the CASP cohort and case control studies checklists [18]. CASP Cohort studies checklist contains twelve questions while CASP Case-control studies checklist contains eleven questions. We included items that evaluated the risk of bias in the studies. The latter six questions on results appraisal were used as a guide to evaluate the results in the Discussion section of this review. The responses were initially classified as either Yes, Can’t Tell or No, as per the CASP checklists. Following that, answers were reclassified according to the level of risk of bias: “Yes” answers were low risk of bias, “Can’t tell” answers were unsure risk of bias, and “No” answers were high risk of bias. Publication bias was not assessed in this review in view of the limited number of included studies providing inaccuracy in the test of asymmetry.
Data synthesis

A narrative review of the included studies was performed as quantitative synthesis could not be performed. For the risk of coronary heart disease outcome, there were 3 studies that met the eligibility criteria. Even though the outcomes measured were all similar (risk of acute-non fatal myocardial infarction), the presentation of palm oil as the exposure was different: daily intake of saturated fatty acids [19], type of vegetable oil used for cooking [20], and pattern of diet of the studied population [21]. In view of the different forms of exposure of palm oil, the results from all of these studies could not be pooled for an overall effect estimate.

The values taken into consideration in this review were the adjusted values of the effect sizes reported by the respective authors because prognostic factors such as co-morbidities, socio-economic status and total energy intake are potential confounding factors that will either under- or overestimate the true effect of the association.

We assessed the quality of evidence of the outcomes using the Grades of Recommendation, Assessment, Development and Evaluation Working Group (GRADE Working Group) framework. The overall quality of evidence was presented in the form of ‘Summary of findings’ table. The assessment of quality was based on five factors: risk of bias across all studies, indirectness, interventions and outcomes, reporting the outcome, inconsistency amongst studies, imprecisions, and publication bias.

Results

We retrieved 1,777 unique citations through our electronic databases search to evaluate the CHD outcomes. Prior to titles and abstracts screening, 122 duplicate articles were removed. A total of 1,655 titles and abstracts were screened based on the eligibility criteria of which 1,640 were excluded based on irrelevant studied population, intervention characteristics or outcomes. Fifteen full text articles were then screened for eligibility of which 11 articles were excluded for the following reasons: 1 for irrelevant intervention, 2 for other vegetable oils used as intervention, 3 for unclear origin of saturated fatty acids, 4 for irrelevant outcomes and 1 for a retracted publication. Subsequently 4 articles remained to be included in the review of which three were for risk of myocardial infarction and one for risk of coronary heart diseases-related mortality. Our search PRISMA flowchart is presented in Fig 1.

Our search for stroke outcomes resulted in 2,738 potentially relevant citations. Following that, 146 duplicates were removed. We screened 2,592 titles and abstracts of which 2,171 articles were removed based on irrelevant studied population, intervention characteristics or outcomes. We then screened for eligibility in 21 full text articles. Twenty full text articles were excluded due to irrelevant intervention (11 articles) and irrelevant outcomes (9 articles). Only one article met the full eligibility criteria for this review. No articles were retrieved for risk of stroke, however one article was included for stroke-related mortality. Our search flowchart and reasons for exclusion for stroke are presented in Fig 2.

Association of palm oil consumption and CHD risk

There were three case-control studies that evaluated the effects of palm oil consumption with CHD risk. Our included studies evaluated palm oil consumption in terms of contribution to daily intake of saturated fatty acids [19], type of vegetable oil used for cooking [20], and pattern of diet of the studied population [21]. The summary of characteristics of included studies is presented in Table 1. All three studies were conducted in Costa Rica and part of the same study. The mean age of participants were 58 years (SD 10.9) for cases and 58 years (SD 11.20) for controls. There were no significant differences in age between the two groups of the studies. In all three studies, the controls were matched for age, gender and area of residence
therefore there were no significant differences for these factors between controls and cases. Number of women recruited was between 26% and 27% of all the participants in these studies.

The cases had significantly higher number of current smokers and individuals with hypertension or diabetes, higher waist-to-hip ratio, lower physical activity and lower household income than the controls. Total daily energy intake, daily intake of saturated and polyunsaturated fat, cholesterol and alcohol consumption were also reported to be significantly higher in cases than in controls.
**Outcomes of included studies.** Kabagambe et al. [19] studied the effects of lauric acid, myristic acid, palmitic acid, stearic acid and total saturated acids for risk of nonfatal acute MI for every 1% increase in energy intake. This association was not significantly different between the two study groups in all fatty acids studied, except for lauric acid. Total saturated fat intake was reported to be associated with risk of MI (OR for the 5th vs 1st quintile of dietary intake = 3.00; 95%CI = 1.54–5.84). Palmitic acid, the highest saturated fat found in palm oil, was also reported to be associated with risk of MI (OR for the 5th vs 1st quintile of dietary intake = 2.76; 95%CI = 1.39–5.47). The trend across the quintiles was however inconsistent. Fried foods contributed to 30% of the total saturated fat intake. Fried foods (40%) and red meat (18%) were the highest contributors of palmitic acid in the study. In the top quintile for intake of fried foods, palm oil (50%) and soybean oil (40%) were the major oils used for
frying. Alternatively, in the lowest quintile, soybean oil (43%) was used more than palm oil (27%). This however did not show any significant impact to the risk of MI. There were no significant differences throughout the different quintiles of intake of fried foods to the risk of MI. The highest consumption of beef and pork also did not show any association with risk of MI.

Table 1. Characteristics of the three included studies reporting the association of palm oil consumption and CHD risk.

| Author and Year | Country | Years of study | Population studied                                                                 | Exposure | Disease ascertainment | Disease outcome | Sample size: cases/controls | Usage of palm oil for cooking | OR (95% CI) | Covariate adjustments                                                                 |
|-----------------|---------|----------------|-------------------------------------------------------------------------------------|----------|-----------------------|------------------|-----------------------------|-----------------------------|-------------|---------------------------------------------------------------------------------------|
| Kabagambe (2003) [19] | Costa Rica | 1995–1998 | Adult Hispanic Americans of Mestizo background, living in Costa Rica | Total SFA, Palmitic acid, stearic acid, lauric acid, myristic acid | MI diagnosed according to the WHO criteria \(^a\) | Non-fatal first acute MI | 485/ 508 | 36% | Total SFA\(^b\): 3.00 (1.54, 5.84) Palmitic acid\(^b\): 2.76 (1.39, 5.47) Stearic acid\(^b\): 3.96 (1.95, 8.01) Fried foods \(^b\): 1.06 (0.59, 1.91) Meat and pork \(^b\): 1.69 (0.93, 3.06) Smoking status, alcohol intake, diabetes, hypertension, angina, waist-to-hip ratio, physical activity, SES, years in current residence, dietary fibre intake, total energy, cholesterol, per cent energy from protein, MUFA, PUFA and trans-fat |
| Kabagambe (2005) [20] | Costa Rica | 1995–2004 | Adult Hispanic Americans of Mestizo background, living in Costa Rica | Type of vegetable oil: palm oil, soybean, other oils\(^c\) | MI diagnosed according to the WHO criteria | Non-fatal first acute MI | 2111/ 2111 | 30% cases, 23% controls | PO vs SO (22% trans-fat): 1.16 (0.86, 1.56) PO vs SO (5% trans-fat): 1.33 (1.09, 1.62) PO vs other oils: 1.26 (1.02, 1.55) Smoking status, alcohol intake, diabetes, hypertension, abdominal obesity, physical activity, income |
| Martinez-Ortíz (2006) [21] | Costa Rica | 1994–1998 | Adult Hispanic Americans of Mestizo background, living in Costa Rica | Dietary pattern: staple, vegetable\(^d\) | MI diagnosed according to the WHO criteria | Non-fatal first acute MI | 496/ 518 | 37% | Staple pattern\(^e\): 3.53 (1.98, 6.31) Vegetable pattern\(^e\): 0.92 (0.57, 1.50) Age, sex, area of residence, total energy intake, smoking status, household income, physical activity, waist-to-hip ratio, diabetes, and hypertension |

CI: Confidence interval, CHD: Coronary heart disease, MI: Myocardial infarction, MUFA: Mono-unsaturated fatty acid, OR: Odds ratio, PO: Palm oil, PUFA: Polyunsaturated fatty acid, SFA: Saturated fatty acids, SES: Socioeconomic status, SO: Soybean oil, WHO: World Health Organisation.

\(^a\) Typical symptoms of myocardial infarction and elevations in cardiac enzyme levels or diagnostic changes in electrocardiogram

\(^b\) Risk estimates of the fifth quintile of dietary intake as compared to the lowest quintile of dietary intake

\(^c\) Other oils were sunflower oil, corn oil, olive oil, canola oil, and less common oils and fats. Percentage of usage in cases and controls were 10% and 11% for soybean oil with 22% trans fat, 39% and 41% for soybean oil with 5% trans fat, and 21% and 25% for other oils, respectively

\(^d\) Staple pattern diet was characterised by increasing intake of palm oil, legumes, refined grains, fresh condiments, coffee, red meat, added sugar, and organ meat, and decreasing intake of other oils, fruit juices, dressings, cold breakfast cereals, pizza, skinless and lean chicken, and low-fat dairy products. Vegetable pattern diet was characterised by higher intake of all vegetables, fruits, skinless and lean chicken, and saccharin, and lower intake of added sugar, chicken and coffee.

\(^e\) Risk estimates of the fifth quintile of factor scores as compared to the lowest quintile of factor scores based on the principal components factor analysis of food groups

https://doi.org/10.1371/journal.pone.0193533.t001
Kabagambe et al. [20] evaluated the different types of cooking oil used in the Costa Rican population. The average trans-fat in soybean oil before 1998 was 22% following which changes in the edible oil industry in Costa Rica resulted in mean trans-fat of 5% in the oil. Odds of developing first non-fatal acute MI was higher in palm oil compared to soybean oil with 5% trans-fat (OR = 1.33; 95%CI = 1.09–1.62) than palm oil compared to soybean oil with 22% trans-fat (OR = 1.16; 95%CI = 0.86–1.56). Nevertheless, these risk estimates were non-significant and imprecise. Palm oil was used for cooking in the homes of 30% of the cases and 23% of controls. We graded this evidence as very low (Table 2).

Martinez-Ortíz et al. [21] looked into the two commonest food patterns in Costa Rica: vegetable pattern and staple pattern diet. Amongst those with a vegetable pattern diet, there was not a significant linear trend in the association with risk of MI and increasing quintiles of factor scores. The factor scores were generated as a result from the principal component analysis of the food groups. The risks of MI amongst those with vegetable pattern diet were also not significant all quintiles (OR for the 5th vs 1st quintile of factor score = 0.92; 95%CI = 0.57–1.50).

Association of palm oil consumption and CVD-related mortality
Both CHD- and stroke-related mortality outcomes were described by the same study [22]. Chen et al. [22] performed a retrospective ecological study between the years 1980 and 1997, including 234 annual observations from Historically High-Income Countries (HIC) and Developing Countries (DC) to evaluate CVD-related mortality with country-level annual total

Table 2. GRADE summary of findings table for the association of palm oil consumption and risk of coronary heart disease.
| Outcomes                                      | Anticipated absolute effects* (95% CI) | Risk with palm oil | Risk with other vegetable oils | Relative effect (95% CI) | Nr of participants (studies) | Certainty of the evidence (GRADE) |
|-----------------------------------------------|---------------------------------------|--------------------|-------------------------------|--------------------------|----------------------------|-------------------------------|
| Palm oil versus other oils                    | Risk with other vegetable oils         | Risk with palm oil  | OR 1.26 (1.02 to 1.55)        | 1077 cases 1014 controls (1 observational study) | ◯◯◯ VERY LOW * |
| Palm oil versus Soybean oil (5%trans-fat)     | Risk with palm oil                     | OR 1.33 (1.09 to 1.62) | 1456 cases 1351 controls (1 observational study) | ◯◯◯ VERY LOW * |
| Palm oil versus Soybean oil (22% trans fat)   | Risk with palm oil                     | OR 1.16 (0.86 to 1.56) | 844 cases 718 controls (1 observational study) | ◯◯◯ VERY LOW * |

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

*a Downgraded one level due to limitation in imprecision of effects (wide and non-significant confidence interval)

https://doi.org/10.1371/journal.pone.0193533.t002

Kabagambe et al. [20] evaluated the different types of cooking oil used in the Costa Rican population. The average trans-fat in soybean oil before 1998 was 22% following which changes in the edible oil industry in Costa Rica resulted in mean trans-fat of 5% in the oil. Odds of developing first non-fatal acute MI was higher in palm oil compared to soybean oil with 5% trans-fat (OR = 1.33; 95%CI = 1.09–1.62) than palm oil compared to soybean oil with 22% trans-fat (OR = 1.16; 95%CI = 0.86–1.56). Nevertheless, these risk estimates were non-significant and imprecise. Palm oil was used for cooking in the homes of 30% of the cases and 23% of controls. We graded this evidence as very low (Table 2).

Martinez-Ortíz et al. [21] looked into the two commonest food patterns in Costa Rica: vegetable pattern and staple pattern diet. Amongst those with a vegetable pattern diet, there was not a significant linear trend in the association with risk of MI and increasing quintiles of factor scores. The factor scores were generated as a result from the principal component analysis of the food groups. The risks of MI amongst those with vegetable pattern diet were also not significant all quintiles (OR for the 5th vs 1st quintile of factor score = 0.92; 95%CI = 0.57–1.50).

The vegetable pattern diet reported approximately 3 times lower odds of nonfatal MI as compared to staple pattern diet, across the similar quintiles. The trend amongst those taking staple pattern diet was however inconsistent across the quintiles, with the odds of the third quintile being the highest (OR = 3.55; 95%CI = 2.05–6.15). Confidence intervals in the point estimates of staple pattern diet were larger than those for the vegetable pattern diet, showing significant variability in the staple pattern diet estimates.

Association of palm oil consumption and CVD-related mortality
Both CHD- and stroke-related mortality outcomes were described by the same study [22]. Chen et al. [22] performed a retrospective ecological study between the years 1980 and 1997, including 234 annual observations from Historically High-Income Countries (HIC) and Developing Countries (DC) to evaluate CVD-related mortality with country-level annual total
domestic consumption of palm oil for food use. Characteristics of the included study are found in Table 3. Throughout the study period, the mortality rates from ischaemic heart disease (IHD) and stroke were declining in HIC but were increasing steadily in DC. There were no significant differences in per-capita palm oil consumption and per-capita coconut oil consumption between HIC and DC at baseline. However, there were significant differences between the two study groups for other major sources of saturated fatty acids (beef, milk, butter, cheese, pork and chicken).

Chen et al. [22] reported that in developing countries, for every additional kilogram of palm oil consumed per-capita annually, IHD mortality rates increased by 68 deaths per 100,000 (95% CI: 21–115). In HIC, the IHD mortality rates increased by 17 deaths per 100,000 (95% CI: 5.3–29) for every additional kilogram of palm oil consumed per-capita annually. Sensitivity analyses were performed for consumption of other major sources of saturated fat, individual country, and other major courses of saturated fat that included beef, pork, chicken, coconut oil, milk, cheese and butter. Nevertheless, there was loss of sample size in the inclusion of other major sources of saturated fat. The sensitivity analysis revealed that despite the increased consumption of other saturated fats the association between palm oil consumption and IHD mortality remained significant. This effect was not seen with consumption of butter and cheese.

In terms of stroke mortality, for every additional kilogram of palm oil consumed per-capita annually, stroke mortality rates increased by 19 deaths per 100,000 (95% CI: -12–49) in DC. While in HIC, for every additional kilogram of palm oil consumed per-capita annually, stroke mortality rates increased by 5.1 deaths per 100,000 (95% CI: -1.2–11). In view of the insignificant association found, the authors reported that sensitivity analyses was not performed for consumption of other major sources of saturated fat and individual country effect. Sensitivity analysis was not reported for stroke mortality. We graded the quality of evidence for the association of palm oil consumption and CVD-related mortality as very low quality (Table 4). The evidences were downgraded three levels due to the limitations in the trial design and imprecision of the effects.

### Risk of bias of included studies

The three case control studies were judged to be at low risk of bias in all domains assessed in this review [19–21]. While the ecological study had two domains with high risk of bias [22]. Detailed risk of bias assessments for each included study is described in S2 Table.
In the study by Chen et al. [22], we rated the selection bias as high risk of bias because the imbalanced number of observations in the two study groups and that the exclusion of the main exporters and consumers of palm oil, Indonesia and Malaysia. This exclusion could have under or overestimated the true differences between the two study groups. The judgement for high risk of bias for confounding factors to Chen et al. [22] was given because of exclusion of important prognostic factors such as diabetes mellitus and hypertension.

Discussion

Findings of this review indicate that there is no evidence of a clear association between palm oil consumption and risk or mortality of cardiovascular diseases, namely coronary heart disease and stroke.

The effect seen between association of palm oil consumption and risk of coronary heart disease were not unique to only palm oil as other food items were included in the analysis therefore the association was insignificant. The association between palm oil consumption and IHD mortality was significant in both developing and historically high-income countries, according to one study with substantial limitations, and a weaker and non-significant association was observed for stroke mortality.

The high proportion of saturated fats, especially palmitic acid, in palm oil have been linked to the increased risk of atherosclerosis [11, 12]. Despite hypercholesterolaemia and atherosclerosis are important determinants of CVD; current evidence for relationship between palm oil consumption and these two determinants is still inconclusive. The difference in the rise of LDL with palm oil consumption as compared to other vegetable oils that are low in saturated fat, is clinically insignificant [23]. In spite of the arguments against palm oil, availability of oleic acid, linoleic acid, vitamin A and vitamin E in palm oil has been shown to be cardioprotective [24, 25]. Furthermore, replacing saturated fats with n-6 PUFA does not result in a significant reduction of CHD events, CHD mortality or total mortality [26].
The results from Kabagambe et al. [19] showed a positive association between a higher intake of saturated fatty acids and risk of nonfatal MI. Palm oil was however, not the only contributor to the intake of saturated fats amongst the Costa Rican population. Dairy products and red meat, for example, were also significant contributors to the total saturated fats in the population studied. We did not investigate the association of individual types of saturated fatty acids in this review, as there is sufficient evidence for this association. Recent evidence no longer supports the claims of atherogenicity of these fats in relation to CVD [27–29]. In a large meta-analysis of observational studies, relative risks for coronary disease were 1.03 (20 studies, 10155 events, 95% CI = 0.98–1.07) [27]. The PURE study recently published reports stating higher saturated fat intake was associated with lower risk of stroke (HR 0.79, 95% CI = 0.64–0.98) in addition to no significant association with risk of myocardial infarction or cardiovascular disease mortality [30].

For cardiometabolic health, the emphasis is on overall diet patterns rather than any single isolated nutrients [31]. INTERSTROKE reported odds of 0.60 (99% CI: 0.53–0.67) to develop stroke with a healthier diet pattern [32]. While INTERHEART suggested that lack of daily consumption of fruits and vegetables contributes to 13.7% of population attributable risk (PAR) [33]. Many studies have evaluated the effect of different patterns of diet in relation to cardiovascular outcomes. Results of the two different patterns of diet by Martinez-Ortíz et al. [21] are in accord with current evidence. Intake of a prudent/healthy diet (characterized by a high intake of vegetables, fruit, legumes, whole grains, and fish and other seafood) is inversely associated with the risk of CVD [34, 35]. Another popular example, Mediterranean diet, has been previously suggested as a good pattern of diet that reduces incidence of cardiovascular diseases [36, 37]. However, the effect seen for primary and secondary prevention of CVD with a Mediterranean diet was very minimal, the odds were 0.64 (95% CI = 0.54–0.75) and 0.69 (95% CI = 0.52–0.93) respectively [34]. The inverse association of the western diet (characterized by a high intake of processed meat, red meat, butter, high-fat dairy products, eggs, and refined grains) has been reported but all of which did not specify the inclusion of palm oil for cooking [34, 38, 39]. Availability of healthier food options might be easily available in high-income countries, but consumption of unhealthy foods was found to be much greater in high-income countries than in middle-income countries [40].

History of hypertension, history of diabetes mellitus, alcohol consumption, physical activity, apolipoprotein (Apo)B/ApoA1 ratio, waist-to-hip ratio, psychosocial factors, smoking, and diet are all known modifiable risk factors of CVD that account for 90% PAR (Population attributable risk) for both coronary heart diseases and stroke [32, 33]. As diabetes and hypertension are major contributors to the risk of CVD, exclusion of these confounders have overestimated the effects seen in Chen et al. [22]. Furthermore, the findings on the roles of cigarette consumption in the study by Chen et al. [22] were at odds with that of other studies [41–44].

While there is no single factor that determines the causality of CVD, emphasis on a global approach is needed to reduce CVD morbidity and mortality. Primarily, significant reduction in CVD risks with intensive control of blood glucose as compared to standard treatment in some studies was reported in some studies [45, 46] but not in other large cohort studies [47–49]. Controlling blood pressure is an important aspect as well as every 10 mm Hg reduction in systolic blood pressure significantly reduced the risk of major cardiovascular disease events [50] with intensive blood pressure-lowering treatment showing significant reduction [51]. Multi-interventional lifestyle modifications are needed for a significant risk reduction of fatal and nonfatal cardiovascular events [52, 53].

We performed an extensive search and systematic synthesis of available evidence by including data from different sources of evidence and looking into the two outcomes: coronary heart diseases and stroke separately. In this review, we only looked for clear involvement of palm oil
as exposure and only direct outcomes. The findings of this review should be interpreted with some caution, owing to the small number of studies included and lack of a pooled effect estimate of the association. The significant bias in selection criteria and confounders of the included studies, the involvement of other food items together with palm oil in the measures of associations, and the possible out-dated trend in the ecological study, in which data analysed stopped two decades ago, limits the validity of our results. The generalisability of our results is also limited by the inclusion of only Costa Rican adults in the case-control studies.

There is a clear need for larger scale and better quality studies to assess the association of palm oil consumption and cardiovascular outcomes. It is essential that these studies: 1) evaluate palm oil consumption more rigorously and quantitatively, 2) analyse consumption of palm oil consumption independent of other food items, 3) are adequately powered and sufficiently prolonged to aid in establishing a dose-response relationship, 4) include the important known prognostic factors of cardiovascular diseases in the analysis, and 5) include the prominent countries consuming palm oil. Scientific evidence of the impact of food and nutrition policy instruments on outcome measures such as food intake and cardiovascular health is also lacking. As red palm oil has shown to have beneficial effects to health, regulations to make its addition mandatory in all the commercially available palm oil should be emphasised.

Conclusion

The present review could not establish strong evidence for or against palm oil consumption with risk and mortality of cardiovascular disease outcomes. The abundance of the availability of palm oil not only as cooking oil, but also in numerous food items makes it challenging to quantify its true association with cardiovascular outcomes. A healthy overall diet should still be prioritised for good cardiometabolic health.

Supporting information

S1 Table. PRISMA checklist.
(DOCX)

S2 Table. Detailed assessment of risk of bias of the included studies.
(DOCX)

Acknowledgments

We would like to thank the Director General of Health Malaysia for his permission to publish this article and Dr Lai Nai Ming for all his guidance and assistance throughout the whole process of this review. We would also like to acknowledge Dr Rimah Melati, Dr Tan Ying Huan, and May Gin Tan for their contributions during the first exercise of this review.

Author Contributions

Conceptualization: Sophia Rasheeqa Ismail.

Formal analysis: Sophia Rasheeqa Ismail, Siti Khuzaimah Maarof, Syazwani Siedar Ali.

Investigation: Sophia Rasheeqa Ismail, Siti Khuzaimah Maarof, Syazwani Siedar Ali, Azizan Ali.

Methodology: Sophia Rasheeqa Ismail.

Project administration: Sophia Rasheeqa Ismail.
Palm oil consumption and cardiovascular diseases

Writing – original draft: Sophia Rasheeqa Ismail.

Writing – review & editing: Sophia Rasheeqa Ismail.

References

1. Vallyathan V. Third International Conference on “Oxygen/nitrogen radicals: Cell injury and disease” Morgantown, West Virginia, June 1–5, 2002. Antioxidants and Redox Signaling. 2002; 4(6):957–60. https://doi.org/10.1089/Ars.2002.4.957 PMID: 12580192.

2. Imoisi OB I G, Agho I, Ekator JO Palm oil, its nutritional and health implications (Review). Journal of Applied Sciences and Environmental Management. 2015; 19(1):127–33.

3. Palm Oil Production European Palm Oil Alliance2016. https://www.palmoilandfood.eu/en/palm-oil-production.

4. Oilseeds: World Markets and Trade. United States Department of Agriculture: Foreign Agricultural Service: 2016.

5. Holub BJ. Clinical nutrition: 4. Omega-3 fatty acids in cardiovascular care. Cmaj. 2002; 166(5):608–15. PMID: 11898942.

6. Grech ED. Pathophysiology and investigation of coronary artery disease. BMJ (Clinical research ed). 2003; 326(7397):1027–30. https://doi.org/10.1136/bmj.326.7397.1027 PMID: 12742929

7. Deb P, Sharma S, Hassan KM. Pathophysiological mechanisms of acute ischemic stroke: An overview with emphasis on therapeutic significance beyond thrombolysis. Pathophysiology. 17(3):197–218. https://doi.org/10.1016/j.pathophys.2009.12.001 PMID: 20074922

8. Page IH, Stare FJ, Corcoran AC, Pollack H, Wilkinson CF Jr. Atherosclerosis and the fat content of the diet. Circulation. 1957; 16(2):163–78. Epub 1957/08/01. PMID: 13447160.

9. Blacket RB, Woodhill J, Mishkel MA. DIET, HYPERCHOLESTEROLAEMIA AND CORONARY HEART DISEASE. Med J Aust. 1965; 1(3):59–63. Epub 1965/01/16. PMID: 14265215.

10. Diet, Nutrition and the Prevention of Chronic Diseases. World Health Organisation (WHO): 2003.

11. Ellie Brown MFJ. Cruel Oil: How Palm Oil Harms Health, Rainforest & Wildlife. Centre for Science in the Public Interest, 2005.

12. Edmond K, Kabagambe AB, Ascherio Alberto, and Campos Hannia. The Type of Oil Used for Cooking Is Associated with the Risk of Nonfatal Acute Myocardial Infarction in Costa Rica. J Nutr. 2005; 135:2674–9. PMID: 16251629

13. Elena Fattore RF. Palm oil and palmitic acid: a review on cardiovascular effects and carcinogenicity. International Journal of Food Sciences and Nutrition. 2013; 64(6):648–59. https://doi.org/10.3109/09637486.2013.768213 PMID: 23406428

14. Sun Y, Neelakantan N, Wu Y, Van Dam RM. Effects of palm oil consumption on blood lipids: A meta-analysis of clinical trials. Circulation Conference: American Heart Association’s Epidemiology and Prevention/Nutrition, Physical Activity, and Metabolism. 2014;129(no pagination). 71447257.

15. Chong YH, Ng TK. Effects of palm oil on cardiovascular risk. The Medical journal of Malaysia. 1991; 46 (1):41–50. Epub 1991/03/01. PMID: 1836037.

16. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed). 2009; 339. https://doi.org/10.1136/bmj.b2700 PMID: 19622552

17. Carol Lefebvre EM, Julie Glanville. 6.4.11.1 The Cochrane Highly Sensitive Search Strategies for identifying randomized trials in MEDLINE: The Cochrane Collaboration; 2011. http://handbook.cochrane.org/chapter_6/6_4_11_1_the_cochrane_highly_sensitive_search_strategies_for.htm.

18. Critical Appraisal Skills Programme (CASP) Checklist Critical Appraisal Skills Programme (CASP). http://www.casp-uk.net/checklists.

19. Kabagambe EK, Baylin A, Siles X, Campos H. Individual saturated fatty acids and nonfatal acute myocardial infarction in Costa Rica. European journal of clinical nutrition. 2003; 57(11):1447–57. Epub 2003/10/25. https://doi.org/10.1038/sj.ejcn.1601709 PMID: 14576756.

20. Kabagambe EK, Baylin A, Ascherio A, Campos H. The type of oil used for cooking is associated with the risk of nonfatal acute myocardial infarction in costa rica. The Journal of Nutrition. 2005; 135 (11):2674–8. Epub 2005/10/28. PMID: 16251629.

21. Martinez-Ortiz JA, Fung TT, Baylin A, Hu FB, Campos H. Dietary patterns and risk of nonfatal acute myocardial infarction in Costa Rican adults. European journal of clinical nutrition. 2006; 60(6):770–7. https://doi.org/10.1038/sj.ejcn.1602381 PMID: 16465200.
Palm oil consumption and cardiovascular diseases

22. Chen BK, Seligman B, Farquhar JW, Goldhaber-Fiebert JD. Multi-Country analysis of palm oil consumption and cardiovascular disease mortality for countries at different stages of economic development: 1980–1997. Globalization and Health. 2011; 7(no pagination)(45).

23. Sun Y, Neelakantan N, Wu Y, Lote-Oke R, Pan A, van Dam RM. Palm Oil Consumption Increases LDL Cholesterol Compared with Vegetable Oils Low in Saturated Fat in a Meta-Analysis of Clinical Trials. The Journal of nutrition. 2015; 145(7):1549–58. Epub 2015/05/23. https://doi.org/10.3945/jn.115.210575 PMID: 25955283.

24. Odia OJ, Ofori S, Maduka O. Palm oil and the heart: A review. World journal of cardiology. 2015; 7(3):144–9. https://doi.org/10.4330/wjc.v7.i3.144 PMID: 25810814.

25. Kritchevsky D, Sundram K. Palm oil in human nutrition: recent advances. Asia Pacific journal of clinical nutrition. 2002; 11 Suppl 7:S393.

26. Hamley S. The effect of replacing saturated fat with mostly n-6 polyunsaturated fat on coronary heart disease: a meta-analysis of randomised controlled trials. Nutrition journal. 2017; 16(1):30. https://doi.org/10.1186/s12937-017-0254-5 PMID: 28526025.

27. Chowdhury R, Wannakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med. 2014; 160(6):398–406. Epub 2014/04/12. https://doi.org/10.7326/M13-1788 PMID: 24723079.

28. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. The American journal of clinical nutrition. 2010; 91(3):535–46. https://doi.org/10.3945/ajcn.2009.277275 PMID: 20071648.

29. de Souza RJ, Mente A, Maroleanu A, Cozma AI, Ha V, Kishibe T, et al. Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. BMJ (Clinical research ed). 2015; 351:h3978. Epub 2015/08/14. https://doi.org/10.1136/bmj.h3978 PMID: 26266892.

30. Dehghan M, Mente A, Zhang X, Swaminathan S, Li W, Mohan V, et al. Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. The Lancet. 2017. Epub 29 August 2017. https://doi.org/10.1016/S0140-6736(17)32252-3.

31. Mozaffarian D. Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity. A Comprehensive Review. 2016; 133(2):187–225. https://doi.org/10.1161/circulationaha.115.018585 PMID: 26746178.

32. O’Donnell MJ, Chin SL, Ranganaraj S, Xavier D, Liu L, Zhang H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. The Lancet. 2016; 388(10046):761–75. https://doi.org/10.1016/S0140-6736(16)30506-2.

33. Yusuf S, Hawken S, Öunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet. 2004; 364(9438):937–52. https://doi.org/10.1016/S0140-6736(04)17019-9.

34. Mente A, De Konin L, Shannon HS, Anand SS. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med. 2009; 169(7):659–69. https://doi.org/10.1001/archinternmed.2009.38 PMID: 19364993.

35. Hou L, Li F, Wang Y, Ou Z, Xu D, Tan W, et al. Association between dietary patterns and coronary heart disease: a meta-analysis of prospective cohort studies. International journal of clinical and experimental medicine. 2015; 8(1):781–90. PMID: 25785058.

36. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. The New England journal of medicine [Internet]. 2013; 368(14):1279–90 pp. Available from: http://onlinelibrary.wiley.com/doi/10.1002/1521-7429.aji120166/fullframe.html.

37. Donat A S, Zerofis NS, Panagiotakos DB, Valis DA. Mediterranean diet and prevention of coronary heart disease in the elderly. Clinical interventions in aging. 2007; 2(1):109–15. PMID: 18044083.

38. Mirmiran P, Bahadoran Z, Vakili A2, Azizi F. Western dietary pattern increases risk of cardiovascular disease in Iranian adults: a prospective population-based study. Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme. 2017; 42(3):326–32. Epub 2017/02/09. https://doi.org/10.1139/apnm-2016-0508 PMID: 28177742.

39. Zhang XY, Shu L, Si CJ, Yu XL, Liao D, Gao W, et al. Dietary Patterns, Alcohol Consumption and Risk of Coronary Heart Disease in Adults: A Meta-Analysis. Nutrients. 2015; 7(8):6562–605. Epub 2015/08/12. https://doi.org/10.3390/nu7085300 PMID: 26262641.

40. Imamura F, Micha R, Khatibzadeh S, Fahimi S, Shi P, Powles J, et al. Dietary quality among men and women in 187 countries in 1990 and 2010: a systematic assessment. The Lancet Global Health. 2015; 3(3):e132–e42. https://doi.org/10.1016/S2214-109X(14)70381-X PMID: 25701991.
41. O’Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010; 376(9735):112–23. Epub 2010/06/22. https://doi.org/10.1016/S0140-6736(10)60834-3 PMID: 20561675.

42. Peters SA, Huxley RR, Woodward M. Smoking as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 81 cohorts, including 3,980,359 individuals and 42,401 strokes. Stroke; a journal of cerebral circulation. 2013; 44(10):2821–8. Epub 2013/08/24. https://doi.org/10.1161/strokeaha.113.002342 PMID: 23970792.

43. Tse LA, Fang XH, Wang WZ, Qiu H, Yu IT. Incidence of ischaemic and haemorrhagic stroke and the association with smoking and smoking cessation: a 10-year multicentre prospective study in China. Public health. 2012; 126(11):960–6. Epub 2012/10/16. https://doi.org/10.1016/j.puhe.2012.07.010 PMID: 23062630.

44. Bhogal RK, Bona CA. B cells: no longer bystanders in liver fibrosis. [Editorial]: Journal of Clinical Investigation November 2005; 115(11):2962–2965.

45. Hayward RA, Reaven PD, Wiltala WL, Bahn GD, Reda DJ, Ge L, et al. Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2015; 372(23):2197–206. https://doi.org/10.1056/NEJMoa1411266 PMID: 26039600.

46. Hemmingsson B, Lund SS, Gluud C, Vaag A, Amdal T, Hemmingsson C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ (Clinical research ed). 2011; 343. https://doi.org/10.1136/bmj.d6898 PMID: 22115901.

47. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. The New England journal of medicine. 2008; 358(24):2545–59. Epub 2008/06/10. https://doi.org/10.1056/NEJMoa0802743 PMID: 18539917.

48. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine. 2008; 358(24):2560–72. Epub 2008/06/10. https://doi.org/10.1056/NEJMoa0802987 PMID: 18539916.

49. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. The New England journal of medicine. 2008; 359(15):1577–89. Epub 2008/09/12. https://doi.org/10.1056/NEJMoa0806470 PMID: 18784090.

50. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet (London, England). 2016; 387(10022):957–67. Epub 2016/01/03. https://doi.org/10.1016/s0140-6736(15)01255-8 PMID: 26724178.

51. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet (London, England). 2016; 387(10017):435–43. Epub 2015/11/13. https://doi.org/10.1016/s0140-6736(15)00805-3 PMID: 26559744.

52. de Waure C, Laurent G-J, Ricciardi W, Ferket B, Teijink J, Spronk S, et al. Lifestyle Interventions in Patients with Coronary Heart Disease. American Journal of Preventive Medicine. 2013; 45(2):207–16. http://dx.doi.org/10.1016/j.amepre.2013.03.020 PMID: 23867029.

53. Janssen V, Gucht VD, Dusseldorp E, Maes S. Lifestyle modification programmes for patients with coronary heart disease: a systematic review and meta-analysis of randomized controlled trials. European Journal of Preventive Cardiology. 2013; 20(4):620–40. https://doi.org/10.1177/2047487312462824 PMID: 23022703.